| 标题： | 肝细胞癌分子靶向药物临床应用中国专家共识（2022版） |
| title： | Chinese Expert Consensus on Clinical Application of Molecular Targeted Drugs for Hepatocellular Carcinoma (2022 edition) |
| 版本： | 更新版 |
| version： | Updated |
| 分类： | 专家共识 |
| classification： | Experts consensus |
| 领域： | 治疗 |
| field： | Treatment |
| 国家和地区： | 中国 |
| Country and region： | China |
| 指南使用者： | 医生 |
| Guide users： | Doctors |
| 证据分级方法： | 表1循证医学证据等级 证据级别 描述 Ⅰa 证据源于对多项随机对照研究的meta分析结果 Ⅰb 证据源于至少一项设计良好的随机对照研究结果 Ⅱa 证据源于至少一项设计良好的前瞻性非随机对照研究结果 Ⅱb 证据源自至少一项设计良好的其他类型干预性临床研究结果 Ⅲ 证据源于设计良好的非干预性研究，如描述性研究、相关性研究等 Ⅳ 证据源于专家委员会报告或权威专家的临床经验报道 表2专家推荐意见级别 证据级别 描述 A 良好的科学证据提示该医疗行为带来明确获益；建议医师对患者实施该医疗行为 B 现有证据表明该医疗行为可带来中度获益，超过其潜在风险；医师可建议或对患者实施该医疗行为 C 现有证据表明该医疗行为可能获益较小，或获益与风险接近；医师可根据患者个体情况有选择地向患者建议和实施该医疗行为 D 现有证据表明该医疗行为无获益，或其潜在风险超过获益；医师不宜向患者实施该医疗行为 I 缺乏科学证据，或现有证据无法评价该医疗行为的获益与风险；医师应帮助患者理解该医疗行为存在的不确定性 |
| Evidence grading method： | Table 1. Levels of evidence-based medicine Evidence level Description Ia Evidence stems from results of a meta-analysis of multiple randomized controlled studies Ib Evidence stems from the results of at least one well-designed randomized controlled study IIa Evidence stems from the results of at least one well-designed prospective non-randomized controlled study IIb Evidence was derived from at least one well-designed interventional clinical study III Evidence stems from well-designed non-interventional studies, such as descriptive studies and correlation studies, among others IV Evidence stems from expert committee reports or reports of clinical experience by authoritative experts Table 2. Expert recommendation level Evidence level Description A Good scientific evidence suggests the clear benefit; physicians are advised to apply the medical behavior to patients B Existing evidence indicates that the medical behavior has a moderate benefit beyond its potential risk; the physician may recommend or perform the medical behavior C Existing evidence indicates that the medical behavior may result in fewer benefits or the benefit is not substantial compared with the risk; the physician may selectively advise and implement the medical behavior D Available evidence indicates that the medical behavior does not have benefits or its potential risks outweigh the benefits; the physician should not perform the medical behavior I A lack of scientific evidence is present, or the available evidence cannot be used to evaluate the benefits versus risks of this medical action; physicians should help patients understand the uncertainties that exist about this medical behavior |
| 制定单位： | 海军军医大学第三附属医院 |
| Formulating unit： | Eastern Hepatobiliary Surgery Hospital, Second Military Medical University |
| 注册时间： | 2022-06-29 |
| Registration time： | |
| 注册编号： | IPGRP-2022CN369 |
| Registration number： | |
| 指南制订的目的： | 为了更好地指导临床实践，中国医师协会肝癌专业委员会完善和更新了《肝细胞癌分子靶向药物临床应用中国专家共识（2022版）》，以供临床医师参考。 |
| Purpose of the guideline： | In order to better guide clinical practice, the Chinese Association of Liver Cancer and Chinese Medical Doctor Association has improved and updated the Chinese Expert Consensus on the Clinical Application of Molecular Targeted Drugs for Hepatocellular Carcinoma (2022 edition) for clinicians' reference. |
